Summary:Purpose: Low-frequency (6 Hz), long-duration (3 s) electrical stimulation in mice produces seizures characterized by immobility, focal clonus, and automatic behaviors reminiscent of human limbic epilepsy. Renewed interest has been expressed in this seizure model with the recognition that it is sensitive to a broad spectrum of anticonvulsants (AEDs) and may have distinct pharmacologic responsiveness from other in vivo tests of AED efficacy. Here we sought to determine whether the progesteronederived neuroactive steroid allopregnanolone (5α,3α-P) and several structural analogues with varying degrees of activity as positive allosteric modulators of γ -aminobutyric acid (GABA) A receptors are protective in the 6-Hz seizure model.Methods: Mice were pretreated with neuroactive steroids (15 min before) or clonazepam (CZP; 30 min before) to 6-Hz corneal stimulation (32 mA). Animals that failed to exhibit immobility were considered protected.
Results:The neuroactive steroids prevented 6-Hz seizures with rank order of potencies (ED 50 values): ganaxolone (6.3 mg/kg) > 5α,3α-P (14.2 mg/kg) ≥ 5β,3α-P (14.4 mg/kg) > 5α,3β-P (>100 mg/kg). CZP also was protective (ED 50 value, 0.075 mg/kg). The potencies of the neuroactive steroids and CZP are similar to their previously reported activities in the pentylenetetrazol (PTZ) seizure model.Conclusions: Neuroactive steroids have comparable potencies in the 6-Hz and PTZ models. Their structural specificity in both models corresponds with their activities as positive allosteric modulators of GABA A receptors, although ganaxolone is more potent than expected, probably because it has greater bioavailability. The 6-Hz model may be a valuable tool in drug development for the identification of GABAergic AEDs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.